Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin Sequential vs Upfront Combination with Chemotherapy in HER2+ Advanced Breast Cancer
NCT00004935Phase 3Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Aug 1999
- Primary completion
- Nov 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of trastuzumab in breast cancer, sponsored by Swiss Group for Clinical Cancer Research. Started Aug 1999; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00004935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004935.